Takeda's $4B TYK2 Drug Outperforms Bristol Myers' Sotyktu
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test https://t.co/aGYIIzQtvG @ByJonGardner $TAK $BMY $ALMS
Sanofi Halts Immune Drug Trial Amid Setback
Sanofi stops immune drug trial in latest research setback https://t.co/DO7ttZF838 by Kristin Jensen $DNTH - 10% $ARGX $SNY - 2%
Merck, Gilead Deliver Mixed Results in Lung Cancer, HIV Trials
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies https://t.co/V5i3QEQmN8 by @Lilah_Alvarado $GILD $MRK $AZN
J&J to Buy Firefly, Securing Degrader Antibody Platform
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B https://t.co/7LR42oP7kZ by @gwendolynawu #biotech $JNJ
Fulcrum Mulls Sale After FDA Halts Sickle Cell Drug
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug https://t.co/NkFQ7vF6Ke by @realJacobBell $FULC - 52%
ASCO26 Highlights Bispecifics, ADCs, RAS Revolution, Prostate Breakthrough
New, from #ASCO26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer https://t.co/rJehfuYEK0 @ByJonGardner and @Lilah_Alvarado $RVMD $MRK $SMMT $JNJ
Allogene CEO Resigns as Agios Drug Flunks Key Test
Allogene CEO to step down; Agios drug fails key test https://t.co/Uvdzw5pNqM $ALLO $AGIO $AZN $ABBV $BBIO
Parabilis Raises $800M, Eyes IPO to Tackle Undruggable Targets
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets https://t.co/hKprr9rkJ4 @ByJonGardner $PBLS #biotech #IPO
Relay Drug Shows Early Promise for Rare Vascular Diseases
Relay drug shows early promise against rare blood vessel diseases https://t.co/WUJw7M1QDc $RLAY + 10% $NVS $OKUR
Merck's China-Licensed ADC Succeeds in First Global Trial
Merck ADC, licensed from China, hits mark in first big global trial https://t.co/tAvLkw6pYm @ByJonGardner $MRK $GILD $AZN
Biotech Execs Rally for Pazdur as Takeda Cuts 4,500 Jobs
#Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers https://t.co/q8ENAYhAJF $ALMS $TAK $AZN $ONC
Lilly Highlights Maintenance Strategies for GLP‑1 Weight Loss
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss https://t.co/LGyx82AJKf by Kristin Jensen $LLY $NVO
Arvinas, Pfizer Secure New Partner for PROTAC Breast Cancer Therapy
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug https://t.co/IKMKNP1Zfk by @Lilah_Alvarado $ARVN $PFE $RIGL + 7%
Viridian Data Boosts Thyroid Eye Disease Drug Prospects
Viridian data lift prospects for thyroid eye disease drug https://t.co/fjfkebQ99D by @Lilah_Alvarado $VRDN + 28% $AMGN
Cytospire Secures $83M to Develop Novel T‑Cell Engager
Cytospire hauls in $83M for a new type of T cell engager https://t.co/19BkL5JiHk by @gwendolynawu #biotech #startups